Filtered By:
Drug: Taxotere
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 2208 results found since Jan 2013.
Predictors of outcomes of docetaxel treatment in de novo metastatic hormone-sensitive prostate cancer: A single-center cohort study
We report a cohort of 73 consecutive patients with de novo mHSPC treated with early docetaxel at the Department of Oncology and Radiotherapy, University Hospital of Split, Croatia, from October 2015 until March 2020. The outcomes analyzed were the occurrence of castration-resistant disease (CRPC) and death from any cause (OS). The median follow-up was 54 (50-73) months. Forty-six (63%) patients developed CRPC and 34 (47%) died during the follow-up. The median time to CRPC and median OS were 16.2 and 58.4 months, respectively. The risk of CRPC was higher for patients with high (above median) values of serum alkaline phospha...
Source: Neoplasma - July 27, 2023 Category: Cancer & Oncology Authors: Tomislav Omr čen Davor Eterovi ć Tea Jozi ć Eduard Vrdoljak Source Type: research
Role of Adverse Events Supervision in Clinical Trials in Neoadjuvant Treatment of
Operable Stage III NSCLC
CONCLUSIONS: Camrelizumab combined with Docetaxel and Cisplatin can be used as a new adjuvant treatment for operable stage III NSCLC. Through the observation and control of AEs, treatment measures can be taken in time to reduce further complications, ensure patient' safety, and ensure the authenticity, scientificity and reliability of clinical trial data.PMID:37488083 | DOI:10.3779/j.issn.1009-3419.2023.102.23
Source: Cancer Control - July 24, 2023 Category: Cancer & Oncology Authors: Yun Zhang Shuang Zhou Wentao Tao Rong Li Source Type: research
Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
CONCLUSION: This study reports real-world evidence showing similar pCR and EFS outcomes with treatment regimens with and without AC and raises awareness of possible overtreatment and long-term toxicity in some patients with HER2+ EBC with the use of AC.PMID:37479867 | DOI:10.1007/s40261-023-01291-6
Source: Clinical Breast Cancer - July 21, 2023 Category: Cancer & Oncology Authors: In ês Soares de Pinho Paulo Luz Lucy Alves Raquel Lopes-Br ás Vanessa Patel Miguel Esperan ça-Martins Lisa Gon çalves Ritas Freitas Diana Sim ão Maria Rold án Galnares Isabel Fernandes Silvia Artacho Criado Salvador Gamez Casado Jose Baena Ca ñada Source Type: research
Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers
This study utilized bulk and single-cell or whole-transcriptome analysis [(RNA sequencing (RNA-seq) and single-cell RNA sequencing (scRNA-seq)], and we observed greater expression of several EMT markers, including Vimentin, hyaluronan synthase-3, S100 calcium binding protein A6, TGFB1, CD44, CD55, and CD109 in European American and African American aggressive variant prostate cancer (AVPC) subtypes-mCRPC, neuroendocrine variant (NEPC), and taxane-resistant. The taxane-resistant gene FSCN1 was also expressed highly in single-cell subclonal populations in mCRPC. Furthermore, metronomic-topotecan single agent and combinations...
Source: Cell Research - July 21, 2023 Category: Cytology Authors: Taraswi Mitra Ghosh Suman Mazumder Joshua Davis Jyoti Yadav Ayuba Akinpelu Ahmed Alnaim Harish Kumar Razan Waliagha Allison E Church Bird Soroush Rais-Bahrami R Curtis Bird Panagiotis Mistriotis Amarjit Mishra Clayton C Yates Amit K Mitra Robert D Arnold Source Type: research
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
Exp Hematol Oncol. 2023 Jul 21;12(1):63. doi: 10.1186/s40164-023-00413-2.ABSTRACTTriplet DCF (docetaxel, cisplatin and 5-flurouracil) and doublet CP/CF (carboplatin and paclitaxel/cisplatin and 5-fluorouracil) regimens were prospectively evaluated in advanced squamous anal cell carcinoma (SCCA), and validated as standard treatments. Even though the high efficacy and good tolerance of DCF regimen were confirmed in 3 independent prospective trials, doublet CP regimen is still recommended in several guidelines based in its better safety profile with similar efficacy compared to CF regimen. We performed a propensity score-adju...
Source: Cancer Control - July 21, 2023 Category: Cancer & Oncology Authors: Stefano Kim V éronique Vendrely Ang élique Saint Thierry Andr é Pauline Vaflard Emmanuelle Samalin Simon Pernot Oliver Bouch é Mustapha Zubir J érôme Desrame Christelle de la Fouchardi ère Denis Smith Fran çois Ghiringhelli Ang élique Vienot Mari Source Type: research
< em > CYP3A < /em > genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study
Front Pharmacol. 2023 Jul 4;14:1178421. doi: 10.3389/fphar.2023.1178421. eCollection 2023.ABSTRACTBackground: Taxane-induced peripheral neuropathy (TIPN) is an important cause of premature treatment cessation and dose-limitation in cancer therapy. It also reduces quality of life and survivorship in affected patients. Genetic polymorphisms in the CYP3A family have been investigated but the findings have been inconsistent and contradictory. Methods: A systematic review identified 12 pharmacogenetic studies investigating genetic variation in CYP3A4*22 and CYP3A5*3 and TIPN. In our candidate gene study, 288 eligible participan...
Source: Cancer Control - July 20, 2023 Category: Cancer & Oncology Authors: Laurence McEvoy Joanne Cliff Daniel F Carr Andrea Jorgensen Rosemary Lord Munir Pirmohamed Source Type: research
SNHG1 opposes quiescence and promotes docetaxel sensitivity in prostate cancer
CONCLUSIONS: Overall, these results indicate SNHG1 has complex roles in prostate cancer, as it stimulates cell cycle entry and disease progression, but sensitizes cells to docetaxel treatment.PMID:37464317 | DOI:10.1186/s12885-023-11006-x
Source: Cancer Control - July 18, 2023 Category: Cancer & Oncology Authors: Steven P Zielske Wei Chen Kristina G Ibrahim Frank C Cackowski Source Type: research
Analgesic efficacy of median nerve stimulation in mice with chemotherapy-induced peripheral neuropathymodulation of brain-derived neurotrophic factor expression
CONCLUSIONS: LFMNS might be an effective non-pharmaceutical option for treating patients suffering from CIPN regulating the expression of peripheral and central BDNF.PMID:37454253 | PMC:PMC10320447 | DOI:10.19852/j.cnki.jtcm.2023.04.005
Source: Journal of Traditional Chinese Medicine - July 16, 2023 Category: Complementary Medicine Authors: Dong-Wook Kang Jae-Gyun Choi Hee Ju Song Jaehyuk Kim Miae Lee Taehee Kim Suk-Yun Kang Yeonhee Ryu Hwa Seung Yoo Jin Sun Lee Jin Bong Park Sang Do Lee Hyun-Woo Kim Source Type: research
